Pharma Journalist -

Regeneron Pharmaceuticals, Inc. and Sanofi announced the primary and all key secondary endpoints were met in a Phase 3 trial evaluating the investigational use of Dupixent (dupilumab)…
Read More...

AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been conditionally approved in China for the treatment of adult…
Read More...

Ono Pharmaceutical Co., Ltd. announced that it has entered into a worldwide drug discovery collaboration agreement with Macomics Ltd, a leader in macrophage drug discovery, to develop…
Read More...

Moderna, Inc. and Generation Bio Co. announced that the two companies have entered into a strategic collaboration to combine Moderna’s biological and technical expertise with core…
Read More...

The good news continues as BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of…
Read More...

Curia announced a collaboration with Corning Incorporated to expand and accelerate continuous-flow development and manufacturing programs for the chemical and biopharmaceutical…
Read More...

Ono Pharmaceutical Co., Ltd. announced that it has entered into a drug discovery collaboration agreement with MOLCURE Inc., to discover and develop innovative antibody drugs for…
Read More...

Roche announced that it has entered into a collaboration with Eli Lilly and Company to support the development of Roche’s Elecsys Amyloid Plasma Panel (EAPP). The EAPP is an innovative…
Read More...

Regeneron Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) has extended the approval of Evkeeza (evinacumab-dgnb) as an adjunct to other lipid-lowering…
Read More...

Biohaven Ltd. announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus…
Read More...